- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01818245
A Study of LY2605541 in Healthy Participants and in the Elderly
Effect of Injection Site on the Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of LY2605541 in Healthy Subjects, and Impact of Body Mass Index and Age on the Pharmacokinetics of LY2605541
This study will include 2 groups (cohorts) of participants:
In Cohort A, this study will look at the amount of LY2605541 that is present in the body after it is injected in 3 different locations in the body of the same participant. At least 16 days will pass between each injection.
In Cohort B, the study will look at how the body absorbs, distributes, and disposes of LY2605541 in participants aged 65 and over.
Participants may enroll in only one cohort.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cohort A: are overtly healthy male or female participants, as determined by medical history and physical examination, aged ≥18 to ≤55 years of age
- Cohort B: are male or female elderly (≥65 years of age) participants that are overtly healthy, or have stable, chronic medical conditions (including Type 2 Diabetes Mellitus [T2DM]) that, in the investigator's opinion, will not significantly alter the disposition of the drug, will not place the participant at increased risk by participating in the study, and will not interfere with interpretation of the data
- Male participants agree to use a reliable method of birth control during the study and for 3 months following the last dose of the investigational product
- Female participants are women of child-bearing potential who test negative for pregnancy at the time of screening based on a urine pregnancy test and agree to use a reliable method of birth control during the study and for 1 month following the last dose of the investigational product
- Female participants are post-menopausal women, or women not of child-bearing potential due to surgical sterilization (at least 3 months after surgical hysterectomy, or at least 3 months after bilateral oophorectomy or bilateral tubal ligation/occlusion with or without hysterectomy) confirmed by medical history, or menopause
- Have a body mass index (BMI) of 18.5 to 40 kilogram per meter square (kg/m^2), inclusive, at time of admission for Period 1
- Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site
Exclusion Criteria:
- Are participants that intend to start a change in diet or lose weight during the study; participants will be expected to maintain their approximate current weight throughout the study
- Are excessive smokers (>10 cigarettes per day); participants who smoke ≤10 cigarettes per day must be able to stop smoking while residing at the clinical research unit (CRU)
Healthy Participants - Cohort A
- Have Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), or a fasting blood glucose (BG) >110 milligrams per deciliter (mg/dL) (6.1 millimoles per liter [mmol/L]) with a glycated hemoglobin (HbA1c) of >6.2%
- Intend to use over-the-counter medication within the 7 days or prescription medication within 14 days prior to dosing (apart from contraceptive medication, vitamin/mineral supplements, occasional paracetamol, thyroxine replacement therapy, and hormone replacement therapy). Antihypertensive and lipid lowering agents are permitted, but must have been administered at stable dose(s) for at least 1 month.
Elderly Participants - Cohort B
- Have T1DM
- Are T2DM participants that require insulin treatment, or have a HbA1c of >10%
- Have started new chronic medication(s) or changed the dose of an existing chronic medication <1 month prior to dosing. Participants are permitted to continue ongoing chronic medications (for example antihypertensive agents, aspirin, non-steroidal anti-inflammatory drugs, lipid lowering agents, thyroxine, hormone replacement therapy, and/or oral anti-diabetic if participants have T2DM). Other stable chronic conditions may be permitted if deemed acceptable by the investigators and Lilly clinical pharmacologist or clinical research physician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY2605541: Cohort A (Injection site: Abdomen)
Participants ≤55 years of age will receive 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods.
There was a washout period of 16-28 days between each treatment period.
|
|
Experimental: LY2605541: Cohort A (Injection site: Upper Arm)
Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods.
There was a washout period of 16-28 days between each treatment period.
|
|
Experimental: LY2605541: Cohort A (Injection site: Thigh)
Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods.
There was a washout period of 16-28 days between each treatment period.
|
|
Experimental: LY2605541: Cohort B (Injection site: Abdomen)
Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)
Time Frame: Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
|
AUC from time zero to infinity (AUC(0-∞)) of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).
|
Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
|
Pharmacokinetics: Observed Maximum Plasma Concentration (Cmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)
Time Frame: Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
|
Cmax of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).
|
Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
|
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Elderly Participants (≥65 Years of Age) Versus Participants ≤55 Years of Age (Abdominal Injection)
Time Frame: Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
|
AUC(0-∞) for LY2605541 was evaluated.
|
Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
|
Pharmacokinetics: Maximum Plasma Concentration (Cmax): Elderly Participants (≥65 Years of Age) Versus Participants ≤55 Years of Age (Abdominal Injection)
Time Frame: Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
|
Cmax of LY2605541 was evaluated.
|
Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamics: Total Amount of Glucose Infused (Gtot): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)
Time Frame: Predose up to 24 hours post clamp procedure in all treatment periods
|
Gtot was evaluated across injection sites (abdominal wall, arm, and thigh).
|
Predose up to 24 hours post clamp procedure in all treatment periods
|
Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)
Time Frame: Predose up to 24 hours post clamp procedure in all treatment periods
|
Rmax was evaluated across injection sites (abdominal wall, arm, and thigh).
|
Predose up to 24 hours post clamp procedure in all treatment periods
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 12152
- I2R-MC-BIDF (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on LY2605541
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedHepatic Insufficiency | Diabetes Mellitus, Type 2 | Healthy VolunteersGermany, Hungary
-
Eli Lilly and CompanyCompletedType 1 Diabetes MellitusUnited States
-
Eli Lilly and CompanyCompletedHealthy VolunteersSingapore
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Germany
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Germany
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 1United Kingdom, United States, Australia, Canada, Poland, Denmark, Spain, Croatia, Sweden, Greece, Belgium, France, New Zealand, South Africa, Israel, Brazil, Ireland, Netherlands, Lithuania, Slovakia
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Brazil, Germany, Israel, Italy, United Kingdom, Australia, Hungary, Puerto Rico, Romania, Russian Federation, Spain, Poland, Canada, Greece, Turkey, Mexico, New Zealand, South Africa, Argentina, Finland, Lithuania, Sl...